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YC Gary Lee1,2,3,5* and Grant W Waterer1,4Abstract
Medical advances have failed to arrest the growing morbidity and mortality from lung diseases. COPD, lung cancer
and pulmonary infections remain leading causes of death. More than any other time in human history, we need
high quality, translatable, patient-focussed respiratory research that will improve clinical practice. Close teamwork of
scientists and clinicians are essential. The results of these work need to be disseminated quickly and widely. The
creation of an open access journal, such as Translational Respiratory Medicine, dedicated to translational respiratory
research can help foster progress.
Keywords: Translational, Respiratory, Pneumonia, Pleural, Research, EmpyemaLung diseases claim more lives now than they ever have.
Chronic obstructive airways disease (COPD) will become
the third leading cause of death according to predictions
by the World Health Organization [1]. Lung carcinomas
kill more people than any other cancers [2] and its in-
creasing occurrence in non-smokers provokes further
concerns. Medical advances over the past centuries have
failed to eradicate lethal microbes such as tuberculosis
[3], which was responsible for 1.4 million deaths in 2011
[4]. Pneumonia and pleural infection [5], once thought
would extinct with advent of antibiotics, are also rising
in incidences.
Advances in respiratory medicine are failing to meet
the growing challenges from a diverse range of lung
diseases [6]. More virulent and drug-resistant respira-
tory pathogens continue to emerge. Multi- (and even
total-) drug resistant M. TB, penicillin-resistant pneumo-
cocci, methicillin-resistant Staphylococcus aureus, and
carbapenem-resistant Enterobacteraciae are now com-
monplace. The massive global impact of SARS and H1N1
2009 influenza A have highlighted how vulnerable man-
kind remains in the ongoing war against our ever-evolving
microbial enemies.* Correspondence: gary.lee@uwa.edu.au
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reproduction in any medium, provided the origMore than any other time in human history, we now
need high quality, translatable, patient-focussed respira-
tory research - and fast! Resources for research are lim-
ited, and prioritization essential. Although ‘pure’ basic
science is vital and major findings (e.g. discovery of the
double helix) have profound implications, translational re-
search to bring bench advances to the bedside is critical.
Success of translational research should be gauged by
how (and how much) the result changes clinical practice.
Meaningful translational research can only be achieved
through close teamwork of scientists and clinicians at
the frontline of clinical care.
The leap is massive from cell biology experiments
performed under optimized laboratory conditions to
successful outcomes in clinical trials which have to in-
corporate numerous inevitable (and uncontrollable)
confounding factors inherent in human diseases. Animal
models may be used to bridge the gap, but faithful
models for human diseases are few and far between. All
too often researchers overlook dissimilarities between
their animal models and the human diseases under
study, and such mistakes have been proven costly. When
promising bench work fails to translate into clinical care,
it sends years of hard work and millions of funding
down the drain. The despair and frustration to the re-
searchers are often beyond description.
Pneumonia research provides many such examples.
Disease-modifying agents such as anti-tumor necrosis
factor-alpha, granulocyte colony stimulating factor ands is an Open Access article distributed under the terms of the Creative
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in animal models but failed dismally in human clinical
trials [7]. In the preclinical models used, pneumonia was
induced acutely by intra-tracheal installation of large bo-
luses of bacteria into animals. This is far removed from
the slow onset of disease in humans which is often also
modified by comorbidities of the host. It is no surprise
that what works well in the mouse pneumonia model
frequently does not work in man.
Another example is the mouse model of a single intra-
tracheal instillation of bleomycin. For many years this
model was used to examine disease pathogenesis and
evaluate therapeutic targets for idiopathic pulmonary fi-
brosis (IPF), despite many differences in the anatomical
distribution, disease chronicity and the level of acute
lung inflammation between human IPF and bleomycin
injured murine lungs. It is nowadays generally accepted
that the bleomycin model is a better model for acute
lung injury and not one of IPF [8].
These examples highlight the need for tight collabor-
ation between bench and clinical researchers. Both must
remain critical of existing models and be highly aware of
the limitations of all in vitro and preclinical models
employed.
Successful examples of translational research
The path from the laboratory to the bedside is now far
more complex than in past decades. The modern ethical
framework for conducting research has created the
necessary barriers to safeguard patient safety. Thank-
fully, no longer can clinicians simply take a drug under
development and experiment it on patients, without evi-
dence of its potential efficacy and safety data on its toxi-
cology and teratogenicity.
The importance of full translational research in the
workup of a therapeutic product is highlighted in the
use of talc for pleurodesis [9,10]. Millions of patients
have received talc pleurodesis since the first report of
talc poudrage in 1935 [11], even though talc has never
been subjected to ‘proper’ laboratory workup and test-
ing. Only half a century later was the observation made
that talc could induce acute respiratory distress syndrome
(ARDS). In subsequent studies, not only did researchers
find impurities in many commercial talc preparations,
they also discovered that talc particles were heterogenous
in size within most products. Animal and human studies,
including randomized trials, found that small talc parti-
cles are often systemically absorbed after their intra-
pleural delivery and induce lung inflammation and ARDS
[12]. Talc-induced respiratory failure can affect up to 9%
of patients, and caused death in 2.3% of the 482 patients
undergoing talc pleurodesis in a multicenter study [13].
Clinical guidelines now recommend only the use of
large particle size talc for pleurodesis [14].On the other hand, there have been many significant
successes in bringing laboratory discoveries to clinical
care through proper translational research and regula-
tory channels. Conjugate pneumococcal vaccines, for ex-
ample, have reduced the burden of disease in children
and adults worldwide since their introduction [15]. Anti-
human immunodeficiency virus agents have prolonged
life expectancy in HIV patients by decades, and the dis-
covery of EGFR mutations in lung cancer have led to
new therapies for those harboring such mutations. Un-
derstanding the pathogenesis of cystic fibrosis (CF) has
led to the first successful introduction of a modulator of
CF transmembrane receptor, albeit only for patients with
a G551D mutation [16].
The role of the translational respiratory medicine
journal
“Research not published is as good as research never
performed”. A journal dedicated to the field of transla-
tional respiratory research can only foster progress. Open
access journals allow wider dissemination of information.
The creation of Translational Respiratory Medicine is
therefore an exciting and right step towards the above
stated goals.
“Good beginning is half the success” as the famous
Chinese saying states. We congratulate Professors Bai,
Matthay and Wang for their effort in establishing the
TRM journal. The other half of the success now depends
on the support from researchers around the world to
rally and support this opportunity of developing a
unique and prestigious forum for translational respira-
tory medicine.
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